영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - montelukast sodium - chewable tablet - 4mg

영국 - 영어 - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - montelukast sodium - chewable tablet - 5mg

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - montelukast sodium - chewable tablet - 5 milligram(s) - leukotriene receptor antagonists; montelukast

탄자니아 - 영어 - Tanzania Medicinces & Medical Devices Authority

msd (pty) limited, south africa - montelukast - tablets, chewable - 4 mg

미국 - 영어 - NLM (National Library of Medicine)

merck sharp & dohme corp. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. singulair is not indicated for the treatment of an acute asthma attack. singulair is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not estab

미국 - 영어 - NLM (National Library of Medicine)

organon llc - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - singulair® is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. singulair is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. singulair is not indicated for the treatment of an acute asthma attack. singulair is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not estab

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 4mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 4mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 5mg

아르메니아 - 영어 - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. - montelukast (montelukast sodium) - tablets chewable - 5mg